Tarsus Pharmaceuticals, Inc.
$65.97
▼
-0.14%
2026-04-21 09:43:01
tarsusrx.com
NMS: TARS
Explore Tarsus Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.86 B
Current Price
$65.97
52W High / Low
$85.25 / $38.51
Stock P/E
—
Book Value
$8.07
Dividend Yield
—
ROCE
-16.64%
ROE
-23.39%
Face Value
—
EPS
$-1.59
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
370
Beta
0.63
Debt / Equity
24.18
Current Ratio
3.85
Quick Ratio
3.82
Forward P/E
25.12
Price / Sales
6.84
Enterprise Value
$2.75 B
EV / EBITDA
-39.82
EV / Revenue
6.1
Rating
Strong Buy
Target Price
$95.11
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Puma Biotechnology, Inc. | $7.37 | 12.05 | $374.96 M | — | 27.62% | 27.97% | $7.9 / $2.75 | $2.59 |
| 2. | Annexon, Inc. | $6.43 | — | $1.05 B | — | -92.11% | -81.9% | $7.18 / $1.4 | $1.42 |
| 3. | Curis, Inc. | $0.62 | — | $24.33 M | — | -558.61% | 2829.1% | $3.13 / $0.49 | $0.42 |
| 4. | AC Immune SA | $2.98 | — | $303.29 M | — | -115.62% | -89.65% | $4 / $1.45 | $0.56 |
| 5. | Allogene Therapeutics, Inc. | $2.42 | — | $582.63 M | — | -53.97% | -53.42% | $4.46 / $0.86 | $1.27 |
| 6. | Septerna, Inc. | $26.86 | — | $1.17 B | — | -15.87% | -12.19% | $32.63 / $5.73 | $8.52 |
| 7. | Alpha Tau Medical Ltd. | $8.11 | — | $706.72 M | — | -44.45% | -61% | $8.6 / $2.5 | $0.88 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 151.67 M | 118.7 M | 102.66 M | 78.33 M | 66.41 M | — |
| Operating Profit | -7.98 M | -14.53 M | -22.18 M | -26.28 M | -24.42 M | — |
| Net Profit | -8.37 M | -12.59 M | -20.34 M | -25.12 M | -23.11 M | — |
| EPS in Rs | -0.2 | -0.3 | -0.48 | -0.59 | -0.54 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 451.36 M | 182.95 M | 17.45 M | 25.82 M |
| Operating Profit | -70.97 M | -120.57 M | -143.16 M | -62.71 M |
| Net Profit | -66.42 M | -115.55 M | -135.89 M | -62.09 M |
| EPS in Rs | -1.56 | -2.72 | -3.19 | -1.46 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 562.16 M | 376.99 M | 265.49 M | 227.86 M |
| Total Liabilities | 218.73 M | 152.46 M | 68.5 M | 34.96 M |
| Equity | 343.43 M | 224.53 M | 196.99 M | 192.9 M |
| Current Assets | 522.78 M | 356.7 M | 256.13 M | 225.38 M |
| Current Liabilities | 135.69 M | 80.61 M | 36.94 M | 15.43 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -12.45 M | -83.03 M | -117.49 M | -49.03 M |
| Investing CF | -42.12 M | -199.19 M | 140.6 M | -144.63 M |
| Financing CF | 143.39 M | 154.66 M | 130.18 M | 93.99 M |
| Free CF | -22.31 M | -89.59 M | -123 M | -49.54 M |
| Capex | -9.86 M | -6.57 M | -5.5 M | -0.51 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 948.62% | -32.42% | — | — |
| Earnings Growth % | 14.97% | -118.86% | — | — |
| Profit Margin % | -63.16% | -778.89% | -240.51% | — |
| Operating Margin % | -65.9% | -820.53% | -242.92% | — |
| Gross Margin % | 92.99% | 90.87% | 96.3% | — |
| EBITDA Margin % | -58.42% | -755.38% | -231.27% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.